NEW YORK (GenomeWeb) – Molecular diagnostics firm Roka Bioscience today reported that its second quarter revenues more than doubled year over year.

The Warren, NJ-based firm, which recently became a publicly traded company, reported revenues of $1.4 million for the three months ended June 30, up from $671,000 a year ago as the number of Atlas instruments placed with commercial customers and the commercial use of the platforms increased. As of the end of the quarter, Roka had 36 instrument placements, up from 21 in the year-ago period, it said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.